世界最新医学信息文摘(连续型电子期刊)
世界最新醫學信息文摘(連續型電子期刊)
세계최신의학신식문적(련속형전자기간)
World Latest Medicine Information
2015年
18期
9-10
,共2页
氯吡格雷%阿司匹林%冠心病
氯吡格雷%阿司匹林%冠心病
록필격뢰%아사필림%관심병
Clopidogrel%Aspirin%Coronary heart disease
目的:探讨氯吡格雷与阿司匹林治疗冠心病的临床疗效及不良反应,为老年冠心病患者提供参考。方法:选取我院2013年1月至2014年1月收治的40例冠心病患者,将患者分成观察组及对照组,分别服用氯毗格雷药物及阿司匹林药物,观察治疗效果。结果:观察组及对照组患者治疗后心绞痛发生次数对比分析后,差异有统计学意义(x2=6.233,P<0.05)。对两组患者治疗后的血小板聚集情况对比分析后,发现观察组患者更低,差异有统计学意义(t=9.124, P<0.05)。观察组患者有1例患者出现不良反应,对照组患者有4例患者出现不良反应。结论:氯吡格雷药物能够对冠心病发挥良好的疗效,患者的安全性更高,值得临床推广。
目的:探討氯吡格雷與阿司匹林治療冠心病的臨床療效及不良反應,為老年冠心病患者提供參攷。方法:選取我院2013年1月至2014年1月收治的40例冠心病患者,將患者分成觀察組及對照組,分彆服用氯毗格雷藥物及阿司匹林藥物,觀察治療效果。結果:觀察組及對照組患者治療後心絞痛髮生次數對比分析後,差異有統計學意義(x2=6.233,P<0.05)。對兩組患者治療後的血小闆聚集情況對比分析後,髮現觀察組患者更低,差異有統計學意義(t=9.124, P<0.05)。觀察組患者有1例患者齣現不良反應,對照組患者有4例患者齣現不良反應。結論:氯吡格雷藥物能夠對冠心病髮揮良好的療效,患者的安全性更高,值得臨床推廣。
목적:탐토록필격뢰여아사필림치료관심병적림상료효급불량반응,위노년관심병환자제공삼고。방법:선취아원2013년1월지2014년1월수치적40례관심병환자,장환자분성관찰조급대조조,분별복용록비격뢰약물급아사필림약물,관찰치료효과。결과:관찰조급대조조환자치료후심교통발생차수대비분석후,차이유통계학의의(x2=6.233,P<0.05)。대량조환자치료후적혈소판취집정황대비분석후,발현관찰조환자경저,차이유통계학의의(t=9.124, P<0.05)。관찰조환자유1례환자출현불량반응,대조조환자유4례환자출현불량반응。결론:록필격뢰약물능구대관심병발휘량호적료효,환자적안전성경고,치득림상추엄。
Objective: To investigate the clinical efficacy of clopidogrel and aspirin in the treatment of coronary heart disease and their adverse reactions, thus providing reference for the elderly patients with coronary heart disease. Methods: 40 patients, who were treated with coronary artery disease in our hospital from January 2013 to January 2014, were divided into an experimental group and a control group. Patients in the experimental group were treated with clopidogrel while those in the control group were treated with aspirin. Then the therapeutic effects of the two groups were observed and compared. Results:After the treatment, the incidences of stenocardia of the two groups have statistically significant difference (x2=6.233, P<0.05) . Platelet aggregation in the observation group was lower than that in the control group. Their difference was statistically significant (t=9.124, P<0.05) . One patient in the observation group was observed to have adverse reactions but four patients in the control group had adverse reactions. Conclusion:Clopidogrel is of excellent clinical effect on the treatment of coronary heart disease. As a result, it is worthy of promotion.